Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (201-210 of 566) with videos related to

Pageof 57
Sort By:
Blood|April 28, 2005
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceS Vincent Rajkumar, Robert A Kyle, Terry M Therneau, et al.
Blood|October 16, 2009
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyHuei-Ting Tsai, Neil E Caporaso, Robert A Kyle, et al.
Blood Cancer Journal|December 5, 2024
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health databaseS Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, et al.
Mayo Clinic Proceedings|December 15, 2006
Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assaysJerry A Katzmann, Angela Dispenzieri, Robert A Kyle, et al.
Blood Cancer Journal|July 8, 2018
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trialsSikander Ailawadhi, Susanna Jacobus, Rachael Sexton, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2011
Early reduction of serum-free light chains associates with renal recovery in myeloma kidneyColin A Hutchison, Paul Cockwell, Stephanie Stringer, et al.
Blood|October 24, 2002
Prognostic value of angiogenesis in solitary bone plasmacytomaShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Leukemia & Lymphoma|December 3, 2005
A phase II trial of imatinib in patients with refractory/relapsed myelomaAngela Dispenzieri, Morie A Gertz, Martha Q Lacy, et al.
Blood|August 1, 2002
Genomic abnormalities in monoclonal gammopathy of undetermined significanceRafael Fonseca, Richard J Bailey, Gregory J Ahmann, et al.
American Journal of Hematology|June 1, 2010
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndromeTrista Stankowski-Drengler, Morie A Gertz, Jerry A Katzmann, et al.
Pageof 57

Showing results (201-210 of 566) with videos related to

Sort By:
Pageof 57
Blood|April 28, 2005
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceS Vincent Rajkumar, Robert A Kyle, Terry M Therneau, et al.
Blood|October 16, 2009
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyHuei-Ting Tsai, Neil E Caporaso, Robert A Kyle, et al.
Blood Cancer Journal|December 5, 2024
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health databaseS Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, et al.
Mayo Clinic Proceedings|December 15, 2006
Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assaysJerry A Katzmann, Angela Dispenzieri, Robert A Kyle, et al.
Blood Cancer Journal|July 8, 2018
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trialsSikander Ailawadhi, Susanna Jacobus, Rachael Sexton, et al.
Journal of the American Society of Nephrology : JASN|April 23, 2011
Early reduction of serum-free light chains associates with renal recovery in myeloma kidneyColin A Hutchison, Paul Cockwell, Stephanie Stringer, et al.
Blood|October 24, 2002
Prognostic value of angiogenesis in solitary bone plasmacytomaShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Leukemia & Lymphoma|December 3, 2005
A phase II trial of imatinib in patients with refractory/relapsed myelomaAngela Dispenzieri, Morie A Gertz, Martha Q Lacy, et al.
Blood|August 1, 2002
Genomic abnormalities in monoclonal gammopathy of undetermined significanceRafael Fonseca, Richard J Bailey, Gregory J Ahmann, et al.
American Journal of Hematology|June 1, 2010
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndromeTrista Stankowski-Drengler, Morie A Gertz, Jerry A Katzmann, et al.
Pageof 57